Lidocaine - Noven Pharmaceuticals

Drug Profile

Lidocaine - Noven Pharmaceuticals

Alternative Names: DentiPatch

Latest Information Update: 01 Apr 2015

Price : $50

At a glance

  • Originator Noven Pharmaceuticals
  • Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Small molecules
  • Mechanism of Action Cell membrane permeability inhibitors; Opioid receptor agonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Dental pain
  • No development reported Allergic rhinitis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 27 Aug 2009 Noven Pharmaceuticals has been acquired by Hisamitsu Pharmaceutical
  • 08 Oct 1999 No-Development-Reported for Allergic rhinitis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top